Suppr超能文献

合并症与 COVID-19 严重程度的关联:系统评价和荟萃分析。

The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis.

机构信息

Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.

Cardio-Oncology Research Center, Rajaie Cardiovascular Medical & Research Center, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Cerebrovasc Dis. 2021;50(2):132-140. doi: 10.1159/000513288. Epub 2021 Feb 2.

Abstract

AIM

Several studies reported the accompaniment of severe COVID-19 with comorbidities. However, there is not a systematic evaluation of all aspects of this association. Therefore, this meta-analysis aimed to assess the association between all underlying comorbidities in COVID-19 infection severity.

METHODS

Electronic literature search was performed via scientific search engines. After the removal of duplicates and selection of articles of interest, 28 studies were included. A fixed-effects model was used; however, if heterogeneity was high (I2 > 50%) a random-effects model was applied to combine the data.

RESULTS

A total of 6,270 individuals were assessed (1,615 severe and 4,655 non-severe patients). The median age was 63 (95% confidence interval [CI]: 49-74) and 47 (95% CI: 19-63) years in the severe and non-severe groups, respectively. Moreover, about 41% of patients had comorbidities. Severity was higher in patients with a history of cerebrovascular disease: OR 4.85 (95% CI: 3.11-7.57). The odds of being in a severe group increase by 4.81 (95% CI: 3.43-6.74) for a history of cardiovascular disease (CVD). This was 4.19 (95% CI: 2.84-6.19) for chronic lung disease and 3.18, 95% CI: 2.09-4.82 for cancer. The odds ratios of diabetes and hypertension were 2.61 (95% CI: 2.02-3.3) and 2.37 (95% CI: 1.80-3.13), respectively.

CONCLUSIONS

The presence of comorbidities is associated with severity of COVID-19 infection. The strongest association was observed for cerebrovascular disease, followed by CVD, chronic lung disease, cancer, diabetes, and hypertension.

摘要

目的

几项研究报告了严重 COVID-19 伴有合并症。然而,目前还没有对这种关联的所有方面进行系统评估。因此,本荟萃分析旨在评估 COVID-19 感染严重程度的所有潜在合并症之间的关联。

方法

通过科学搜索引擎进行电子文献检索。在去除重复项并选择感兴趣的文章后,共纳入 28 项研究。使用固定效应模型;然而,如果异质性较高(I2 > 50%),则应用随机效应模型来合并数据。

结果

共评估了 6270 人(1615 例严重患者和 4655 例非严重患者)。严重组和非严重组的中位年龄分别为 63(95%置信区间[CI]:49-74)和 47(95% CI:19-63)岁。此外,约 41%的患者存在合并症。患有脑血管疾病史的患者病情更为严重:OR 4.85(95% CI:3.11-7.57)。心血管疾病(CVD)病史使患者进入严重组的几率增加 4.81(95% CI:3.43-6.74)。慢性肺部疾病使进入严重组的几率增加 4.19(95% CI:2.84-6.19),癌症使进入严重组的几率增加 3.18(95% CI:2.09-4.82)。糖尿病和高血压的比值比分别为 2.61(95% CI:2.02-3.3)和 2.37(95% CI:1.80-3.13)。

结论

合并症的存在与 COVID-19 感染的严重程度有关。最强的关联是脑血管疾病,其次是 CVD、慢性肺部疾病、癌症、糖尿病和高血压。

相似文献

1
The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis.
Cerebrovasc Dis. 2021;50(2):132-140. doi: 10.1159/000513288. Epub 2021 Feb 2.
3
Comorbidities' potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis.
Medicine (Baltimore). 2021 Mar 26;100(12):e24971. doi: 10.1097/MD.0000000000024971.
4
Cardio-Cerebrovascular Disease is Associated With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis.
Biol Res Nurs. 2021 Apr;23(2):258-269. doi: 10.1177/1099800420951984. Epub 2020 Aug 27.
5
Features of severe COVID-19: A systematic review and meta-analysis.
Eur J Clin Invest. 2020 Oct;50(10):e13378. doi: 10.1111/eci.13378. Epub 2020 Aug 29.
6
Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.
Diabetes Obes Metab. 2020 Oct;22(10):1915-1924. doi: 10.1111/dom.14124. Epub 2020 Jul 16.
7
Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature.
Am J Infect Control. 2021 Feb;49(2):238-246. doi: 10.1016/j.ajic.2020.06.213. Epub 2020 Jul 10.
8
Cardiovascular comorbidities as predictors for severe COVID-19 infection or death.
Eur Heart J Qual Care Clin Outcomes. 2021 Mar 15;7(2):172-180. doi: 10.1093/ehjqcco/qcaa081.
10
The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study.
PLoS One. 2021 Feb 16;16(2):e0246190. doi: 10.1371/journal.pone.0246190. eCollection 2021.

引用本文的文献

1
Prevalence of comorbidities and their association with disease severity and mortality in COVID-19 patients: A systematic review and meta-analysis.
J Multimorb Comorb. 2025 Aug 28;15:26335565251371256. doi: 10.1177/26335565251371256. eCollection 2025 Jan-Dec.
3
Evaluation of suPAR as a Key Prognostic Biomarker in Patients with SARS-CoV-2 Pneumonia.
Biomedicines. 2025 Apr 8;13(4):896. doi: 10.3390/biomedicines13040896.
5
Outcomes of COVID-19 in Pregnant Women: A Retrospective Analysis of 300 Cases in Jordan.
Healthcare (Basel). 2024 Oct 23;12(21):2113. doi: 10.3390/healthcare12212113.
6
Evaluating the Governance Ability of Urban Public Health Using EM-AHP-TOPSIS Method: A Case Study in China.
Iran J Public Health. 2024 Aug;53(8):1815-1825. doi: 10.18502/ijph.v53i8.16287.
7
Household preparedness for emergencies during COVID-19 pandemic among the general population of Nepal.
PLOS Glob Public Health. 2024 Sep 12;4(9):e0003475. doi: 10.1371/journal.pgph.0003475. eCollection 2024.
8
Clinical profiles and mortality predictors of hospitalized patients with COVID-19 in Ethiopia.
BMC Infect Dis. 2024 Sep 2;24(1):908. doi: 10.1186/s12879-024-09836-6.

本文引用的文献

1
COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities.
Med J Islam Repub Iran. 2020 Nov 2;34:147. doi: 10.34171/mjiri.34.147. eCollection 2020.
2
Role of vitamin D in pathogenesis and severity of COVID-19 infection.
Arch Physiol Biochem. 2023 Feb;129(1):26-32. doi: 10.1080/13813455.2020.1792505. Epub 2020 Oct 30.
3
Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis.
Int J Public Health. 2020 Jun;65(5):533-546. doi: 10.1007/s00038-020-01390-7. Epub 2020 May 25.
4
SARS-COV-2 infection in children and newborns: a systematic review.
Eur J Pediatr. 2020 Jul;179(7):1029-1046. doi: 10.1007/s00431-020-03684-7. Epub 2020 May 18.
5
Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19).
Respir Med. 2020 Jun;167:105941. doi: 10.1016/j.rmed.2020.105941. Epub 2020 Mar 24.
7
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.
JAMA Neurol. 2020 Jun 1;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127.
8
Diabetes is a risk factor for the progression and prognosis of COVID-19.
Diabetes Metab Res Rev. 2020 Oct;36(7):e3319. doi: 10.1002/dmrr.3319. Epub 2020 Apr 7.
9
10
Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis.
Pol Arch Intern Med. 2020 Apr 30;130(4):304-309. doi: 10.20452/pamw.15272. Epub 2020 Mar 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验